SWOG clinical trial number
SWOG-9126

A Controlled Trial of Cyclosporine as a Chemotherapy- Resistance Modifier in High Risk Acute Myeloid Leukemia, Phase III

Closed
Phase
III
Accrual
100%
Published
Abbreviated Title
A Controlled Trial of Cyclosporine as a Chemotherapy- Resistance Modifier in High Risk Acute Myeloid Leukemia, Phase III
Activated
03/01/1993
Closed
03/01/1998

Research committees

Leukemia

Publication Information Expand/Collapse

2017

The effect of positive SWOG treatment trials on survival of patients with cancer in the US population

JM Unger;M Leblanc;CD Blanke JAMA Oncology Oct 1;3(10):1345-1351

PMid: PMID28586789; PMC5710507

The impact of positive SWOG treatment trials on population survival

J Unger;M LeBlanc;C Blanke J Clin Oncol 35, 2017 (suppl; abstr 6513); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster discussion

2015

Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia

B Medeiros;M Othus;M Fang;F Appelbaum;H Erba Haematololgica Mar;100(3):331-335

PMid: PMID25527568 | PMC number: PMC4349271

2014

Unsuccessful cytogenetic analysis is a poor prognostic feature in acute myeloid leukemia

B Medeiros;M Othus;E Estey;M Fang;F Appelbaum British Journal of Haematology 28(2):245-250;

PMid: PMID24383844 | PMC number: PMC4117470

Declining rates of treatment-related mortality in patients with newly-diagnosed AML given "intense" induction regimens: a report from SWOG and MD Anderson

M Othus;H Kantarjian;S Petersdorf;F Ravandi;J Godwin;J Cortes;S Pierce;H Erba;S Faderl;F Appelbaum;E Estey Leukemia 28(2):289-292;

PMid: PMID23760400 | PMC number: PMC4457325

2013

The prognostic significance of IRF8 transcripts in adult patients with acute myeloid leukemia

E Pogosova-Agadjanyan;K Kopecky;S Meshinchi;F Appelbaum;J Anderson;J Godwin;H Lee;A List;V Oehler;S Petersdorf;J Radich;C Willman;D Stirewalt PlosOne 8(8):e70812;

PMid: PMID23967110 | PMC number: PMC3743845

2012

Impact of residual normal metaphases in core binding factor acute myeloid leukemia

B Medeiros;M Othus;M Fang;F Appelbaum;E Estey Cancer 118(9):2420-2423;

PMid: PMID21928314 | PMC number: PMC3490403

Impact of body-mass index in the outcome of adult patients with acute myeloid leukemia

B Medeiros;M Othus;EH Estey;M Fang;F Appelbaum Haematologica 97(9):1401-1404

PMid: PMID22315487 | PMC number: PMCID3436242

Declining rates of treatment-related mortality recent in patients with newly-diagnosed AML given "intense" induction regimens: a report from SWOG and MD Anderson

M Othus;H Kantarjian;S Petersdorf;F Ravandi;J Godwin;J Cortes;S Pierce;H Erba;S Faderl;F Appelbaum;E Estey Blood 120(21):abst. 129; American Society of Hematology Annual Meeting, oral;

2011

Expression of topoisomerase II isoforms a and B in adult patients with acute myeloid leukemia (AML): relationship to immunophenotype and treatment outcome

A Michelson;K Kopecky;E Koegle;J Anderson;J Godwin;S Petersdorf;A List;C Willman;F Appelbaum;J Radich;M Ganapathi;R Ganapathi;A Advani Journal of Clinical Oncology 29:(suppl; abstr 6564) ASCO 2011 meeting, general poster presentation

Influence of residual normal metaphases in acute myeloid leukemia patients with monosomal karyotype [PMID21330329; PMC3069244]

B Xie;M Othus;B Medeiros;M Fang;F Appelbaum;E Estey Haematologica 96(4):631-632

Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation [PMID21680797;PMC3156042]

M Fang;B Storer;E Estey;M Othus;L Zhang;B Sandmaier;F Appelbaum Blood 118(6):1490-1494

Cytarabine dose for acute myeloid leukemia. (Letter to the Editor) [PMID21631340]

B Medeiros;M Othus;F Appelbaum New England Journal of Medicine 364(11):2167-2168

Prediction of early death following induction therapy for newly diagnosed acute leukemia with pretreatment risk scores: a novel paradigm for treatment assignment

R Walter;M Othus;G Borthakur;F Ravandi;J Cortes;S Pierce;F Appelbaum;H Kantarjian;E Estey Journal of Clinical Oncology, 29(33):4417-23;

PMid: PMID21969499 | PMC number: PMC3221524

2010

The effect of complete remission (CR) and CR with incomplete platelet recovery (CRp) on outcome in acute myeloid leukemia: a combined eastern cooperative oncology group (ECOG), Southwest Oncology Group (SWOG), and M.D. Anderson Cancer Center study

Journal of Clinical Oncology 28(10):1766-1771;

Prognostic impact of monosomal karyotype in young adults and elderly acute myeloid leukemia: the Southwest Oncology Group experience [PMID: 20562328; NIHMSID244631]

BC Medeiros;M Othus;M Fang;D Roulston;FR Appelbaum Blood 116(13):2224-2228

PMid: PMID20562328 | PMC number: PMC3709629

Over-expression of novel IRF8 splice variants is associated with a significant decrease in relapse-free survival in adult AML patients

E Porosova-Agadjanyan;K Kopecky;H Lee;J Anderson;J Godwin;A List;S Meshinchi;V Oehler;S Petersdorf;C Willman;F Appelbaum;JP Radich;D Stirewalt Blood 116:Abstract 1679; American Society of Hematology Annual Meeting; poster

Influence of residual normal metaphases in patients with monosomal karyotype

B Xie;M Othus;B Medeiros;M Fang;F Appelbaum;E Estey Blood 116:Abstract 1671; ASH 2010 meeting; poster presentation

2009

Very late antigen-4 (VLA-4) function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia [PMC2630271; PMID18927435]

PS Becker;KJ Kopecky;AN Wilks;JM Harlan;CL Willman;SH Petersdorf;T Papayannopoulou;FR Appelbaum Blood 113(4):866-874

2008

The Southwest Oncology Group: progress in cancer research [PMID18929152]

CA Coltman Seminars in Oncology 35(5):545-552

2006

Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction.

CS Wilson;GS Davidson;SB Martin;E Andries;J Potter;R Harvey;K Ar;Y Xu;KJ Kopecky;DP Ankerst;H Gundacker;ML Slovak;M Mosquera-Caro;IM Chen;DL Stirewalt;M Murphy;FA Schultz;H Kang;X Wang;JP Radich;FR Appelbaum;SR Atlas;J Godwin;CL Willman Blood 108(2):685-696

The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations.

FR Appelbaum;KJ Kopecky;MS Tallman;ML Slovak;HM Gundacker;HT Kim;GW Dewald;HM Kantarjian;SR Pierce;EH Estey British Journal of Haematology 135:165-173

2001

Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia. a Southwest Oncology Group study

AF List;KJ Kopecky;CL Willman;DR Head;DL Persons;ML Slovak;R Dorr;C Karanes;HE Hynes;JH Doroshow;M Shurafa;FR Appelbaum Blood 98(12):3212-3220

2000

Microsatellite Instability is not a defining genetic feature of acute myeloid leukemogenesis in adults: results of a retrospective study of 132 patients and review of the literature

LM Rimsza;KJ Kopecky;J Ruschulte;I-M Chen;ML Slovak;C Karanes;J Godwin;A List;CL Willman Leukemia 14:1044-1051

1998

Benefit of cycloporine (CsA) modulation of anthracycline resistance in high-risk AML: A Southwest Oncology Group (SWOG) study.

AF List;KJ Kopecky;CL Willman;C Spier;R Dorr;L Flaherty;H Hynes;F Appelbaum Blood 92(10)(Suppl.1):312a(#1281)

1997

Trisomy 10 as the sole cytogenetic abnormality in hematologic neoplasia.

K Theil;SM Dobin;T McConnell;ML Slovak;S Kahwash;M Brownell;A Chaudhury Blood 90(10):223b(#3742)

1993

Functional assessment of the multidrug (MDR1) resistance efflux pump in acute myeloid leukemia (AML): Identification of CD34-, CD33+, MRK16+ (MDR1+) cases lacking functional dye efflux.

CP Leith;KJ Kopecky;IM Chen;BB Griffith;FR Appelbaum;CL Willman Blood 82(10)(Suppl.1):(#1754)

Multidrug resistance: clinical relevance in acute leukemia

AF List Oncology 7(10):23-32